Roche has again extended the deadline for its tender offer for Spark Therapeutics saying U.S. and British anti-trust authorities need additional time to review the deal.
Roche has pushed the deadline several times since it announced the $4.3 billion offer to buy the gene therapy company back in February. The first extension happened because Roche only received support from holders with 29.4 percent of Spark shares while it required a majority. Further delays were due to anti-trust reviews.
The offer, which was originally due to expire on Nov. 25, has now been extended to Dec. 10.
Read the Reuters coverage